PBLS
Parabilis Medicines, Inc. Common Stock
Nasdaq · usd
Parabilis Medicines, Inc. Common Stock (PBLS) trades at $26.77 (-5.24%) as of 4:02:15 AM EST on Nov 19, 2026, +5.13% over the past month. Market cap is $3.57B, with 8.3 days to cover in short interest.
Stock performance
How Parabilis Medicines, Inc. Common Stock (PBLS) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.78%
- 1W
- -3.98%
- 1M
- +5.13%
- YTD
- -9.91%
- 1Y
- -9.91%
- 52-wk range
- $22.66 – $42.49
Key statistics
Today's trading snapshot for PBLS: day range, open, previous close, volume and market cap.
- Day range
- $27.70 – $29.26
- Open
- $28.22
- Prev close
- $28.25
- Volume
- 602.37K
- Market cap
- $3.57B
- Shares out
- 125.26M
8-K filings
Material corporate events Parabilis Medicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Parabilis Medicines, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.
- Lease agreementNov 5, 2026
On October 30, 2026, Parabilis Medicines, Inc. and LS 400/500 CDP, LLC entered into a Third Amendment of Lease, which amends the Lease regarding the Company's corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts. The Amendment provides for an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet at 20 Acorn Park Drive, an extension of the lease term through December 31, 2037, and options for further five-year extensions.
- Executive compensation changeSep 2, 2026
In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits pursuant to the terms of his employment agreement with the Company.
- Executive compensation changeAug 25, 2026
In accordance with the Company's compensation program for non-employee directors, Mr. Tendler received an equity award consisting of a stock option to purchase 20,294 shares of the Company's common stock at an exercise price of $39.36 per share. The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant... Mr. Tendler will also receive an annual retainer of $40,000 for Board service and $7,500 for Science & Technology Committee service, each to be paid quarterly in arrears.
- Investor presentationAug 13, 2026
On August 13, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the investor relation page of the Company's website at https://parabilismed.com/. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
PBLS short interest
How heavily PBLS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.3
- Short interest
- 11.05M
- Avg volume
- 1.33M
As of · reported to FINRA twice monthly.
PBLS news
The latest news and headlines about Parabilis Medicines, Inc. Common Stock (PBLS).
- Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?positiveZacks Investment Research· Nov 17, 2026
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorspositiveGlobeNewswire Inc.· Oct 24, 2026
- Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of DirectorspositiveGlobeNewswire Inc.· Aug 25, 2026
- Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?neutralThe Motley Fool· Jun 12, 2026
- Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· Jun 11, 2026
Frequently asked questions
What is the Parabilis Medicines, Inc. Common Stock (PBLS) stock price today?
Parabilis Medicines, Inc. Common Stock (PBLS) is trading at $26.77 (-5.24% on the day) as of 4:02:15 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Parabilis Medicines, Inc. Common Stock?
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases.
What is the short interest in PBLS?
As of Oct 30, 2026, PBLS has 11.05M shares short and 8.3 days to cover.
What exchange is PBLS listed on?
Parabilis Medicines, Inc. Common Stock (PBLS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of PBLS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a PBLS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.